



Acquisition Opportunity

Intellectual Property and Related Assets
of a Clinical-Stage Biotherapeutics Company
Focused on the Development of Therapies in the
Treatment of Cardiopulmonary Diseases

Accepting Offers



Gabe Fried
CEO
617.458.9355



Adam Snyder
Senior Patent Analyst
440.465.5422



Stella Silverstein
Analyst
646.651.1953

Contact Us

Project+BLPH@HilcoGlobal.com


www.HilcoStreambank.com

Overview

Hilco Streambank has been engaged by Bellerophon Therapeutics to sell the company's intangible and tangible assets portfolios, including patents and applications, along with supporting clinical and device data, knowhow, and bespoke inventory.




Bellerophon is a **clinical-stage biotherapeutics company** focused on the development of innovative therapies that address significant unmet medical needs in the treatment of **cardiopulmonary diseases**. The company is in the process of winding down operations and Hilco Streambank is requesting bids by **December 11, 2023**.

Bellerophon's primary program is its proprietary **INOpulse platform technology**. INOpulse integrates a pressurized cartridge of nitric oxide (NO) with a smart delivery device that doses NO based on breath detection, and a patented tri-lumen cannula which can also incorporate oxygen therapy.



INOpulse Technology

Bellerophon's innovative technology uses the three components to modulate the **administration of NO based on breathing rate**, so the patient is receiving a constant dose over time regardless of inhalation type. The INOpulse technology is designed to be **lightweight and portable**, allowing it to be used for chronic treatment outside of the hospital providing access to a broad range of **high value indications**.



01

Intuitive and easy to use device delivers pulsed doses of nitric oxide to the patient

02

Drug cartridge engages with device via a simple swing mechanism

03

Novel tri-lumen cannula allows concomitant delivery of nitric oxide and oxygen therapy

04

Lightweight portable design allows ease of transport for home use by ambulatory patients

The INOpulse Delivery System is ISO 13485 Certified and CE Marked.

Patented Cannula Technology


The novel cannula's three lumens each perform a particular function:

**Lumen 1:
nitric oxide
delivery**

**Lumen 2:
breath
detection**

**Lumen 3:
connection to
standard oxygen
therapy**

This lumen acts as a **breath detection tube**, sensing differentials in pressure based on the patient's breathing type; it sends this information to the delivery device where it is integrated into a **proprietary algorithm** which dictates the rate at which the valve opens to administer the treatment.



Available Assets

Bellerophon Patent Portfolio

104 active patents at various stages of prosecution (93 worldwide, 11 US Applications) across 10+ patent families that could extend protection to 2041. Coverage includes 18 jurisdictions: US, AR, AU, BR, CA, CN, EP, EA, HK, IL, IN, JP, KR, MX, PH, SG, TW, WO.

In-Licensed Patent Portfolio

128 active patent at various stages of prosecution (31 USGs, 4 US applications, 2 US design patents, and 91 worldwide counterparts) across 10+ patent families in 18 jurisdictions including US, AU, BR, CA, CN, EA, EP, HRP, HUE, IL, JP, KR, LT, MX, PT, SG, SI, ZA.

In-License Agreement

Provides exclusive global rights to the use of 6 high-value indications: fILD, PH-Sarcoidosis, PH-COPD, PAH, CTEPH, and High-Altitude Sickness.

Supporting Materials

Clinical data, device data, manufacturing knowhow, and other supporting materials.

Inventory

Approx. \$8 million at original cost worth of GMP (Good Manufacturing Practice) and non-GMP inventory available for use in clinical and non-clinical programs, including INOpulse devices, cartridges, and cannula kits.



Accepting Offers



Please contact Hilco Streambank directly to learn more about the sale process and to request a non-disclosure agreement for access to a virtual data room containing additional materials.

Contact us at [**Project+BLPH@HilcoGlobal.com**](mailto:Project+BLPH@HilcoGlobal.com)